On February 21, 2018 Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, reported it has been accepted to present preclinical data demonstrating that its Chk1 inhibitor, SRA737, synergizes with niraparib, a poly ADP-ribose inhibitor (PARPi), in a poster at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2018 being held in Chicago, Illinois from April 14-18 (Press release, Sierra Oncology, FEB 21, 2018, View Source [SID1234524082]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There is a strong biological rationale for synergy between SRA737 and PARP inhibition, which is further validated by these data. Notably, this combination was effective in homologous repair proficient tumor cell lines where PARP inhibitors are substantially less active in the clinical setting," said Dr. Christian Hassig, Chief Scientific Officer of Sierra Oncology. "Sierra is designing a potential clinical study to evaluate SRA737 in combination with a PARP inhibitor, including evaluation in comparable patient populations."

Poster Title: The Chk1 inhibitor, SRA737, synergizes with niraparib to kill cancer cells via multiple cell death pathways
Session Category: Experimental and Molecular Therapeutics
Session Title: Cell Cycle, Drug Resistance, and Combinations
Session Date and Time: Monday Apr 16, 2018 8:00 AM – 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 37
Poster Board Number: 11
Permanent Abstract Number: 1853

The Poster will be available April 16, 2018 on the company’s website at www.sierraoncology.com.

On February 21, 2018 PDL BioPharma, Inc. presented the 2018 RBC Capital Market’s Global Healthcare Conference presentation (Presentation, PDL BioPharma, FEB 21, 2018, View Source [SID1234524081]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 21, 2018 FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, reported that it will report fourth quarter and full year 2017 financial results on Tuesday, February 27, 2018 after market close, and will host a conference call to discuss financial results and provide a business update at 5:00 p.m. ET (2:00 p.m. PT) (Press release, FibroGen, FEB 21, 2018, View Source;p=RssLanding&cat=news&id=2333605 [SID1234524080]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 46307822#.

Dial-In Information
Live (U.S./Canada): (888) 771-4371
Live (International): (847) 585-4405
Confirmation number: 46307822

On February 21, 2018 AVEO Oncology reported that it will present at the RBC Capital Markets Healthcare Conference
Wednesday, February 21, 2018 10:00 a.m. ET (Press release, AVEO, FEB 21, 2018, View Source;p=RssLanding&cat=events&id=5268350 [SID1234524064])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

EVENT DETAILS
Title AVEO Oncology at the RBC Capital Markets Healthcare Conference
Date and Time Wednesday, February 21, 2018 10:00 a.m. ET

On February 20, 2018 Nordic Nanovector ASA (OSE: NANO) reported its fourth quarter and full year 2017 results on Tuesday, 27th of February 2018 (Press release, Nordic Nanovector, FEB 20, 2018, View Source [SID1234553512]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A presentation by Nordic Nanovector’s senior management team will take place at 8:30 am CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: NYLAND

The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2017 from 7:00 am CET the same day.